Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, TNBC - Triple-Negative Breast Cancer, Triple-negative Breast Carcinoma
Conditions
Brief summary
This is a single institution, open-label randomized phase 1 trial of neoantigen DNA vaccine alone vs. neoantigen DNA vaccine plus durvalumab in triple negative breast cancer (TNBC) patients following standard of care therapy. Patients with newly diagnosed clinical stage II-III TNBC are eligible for enrollment. Patients will receive standard of care therapy including chemotherapy, surgery and radiation therapy as clinically indicated. Following standard of care therapy, patients will be randomized to receive either a neoantigen DNA vaccine alone, or a neoantigen DNA vaccine + durvalumab.
Interventions
DRUGDurvalumab
-Human monoclonal antibody
BIOLOGICALNeoantigen DNA vaccine
-The vaccine will be given by the TDS-IM system
DEVICETDS-IM system (Inchor Medical Systems)
-At each vaccination time point, patients will receive two injections at separate sites.
PROCEDUREPeripheral blood draw
-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
Sponsors
MedImmune LLC
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Washington University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of invasive breast cancer. * ER and PR less than Allred score of 3 or less than 1% positive staining cells in the invasive component of the tumor. Patients not meeting this pathology criteria, but have been clinically treated as having TNBC, may be enrolled at treating physician's discretion. * HER2 negative by FISH or IHC staining 0 or 1+. * Consented for genome sequencing * Clinical stage T1c-T4c, any N, M0 primary tumor by AJCC 7th edition clinical staging prior to neoadjuvant chemotherapy, with residual invasive breast cancer after neoadjuvant therapy. * At least 18 years of age. * Eastern Cooperative Oncology Group (ECOG) performance status ≥1. * Adequate organ and marrow function no more than 14 days prior to registration as defined below: * absolute neutrophil count ≥1,500/μL * platelets ≥100,000/μL * hemoglobin ≥ 9.0 g/dL * total bilirubin ≤ 1.5 X institutional upper limit of normal * AST/ALT ≤2.5 X institutional upper limit of normal * serum creatinine clearance \>40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance * Body weight \> 30 kg. * Evidence of post-menopausal status or negative urine or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). * Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). * Able to understand and willing to sign an IRB-approved written informed consent document.
Exclusion criteria
* Received chemotherapy, radiotherapy (to more than 30% of the bone marrow or with a wide field of radiation), or biologic therapy within the last 30 days. * Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. * Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days. * Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab. * Major surgical procedure within 28 days prior to the first dose of durvalumab. Local surgery of isolated lesions for palliative intent is acceptable. * Current use or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal, inhaled, and intra-articular corticosteroids or systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid. * Known metastatic disease. * Invasive cancer in the contralateral breast. * Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty. * History of hypersensitivity to durvalumab or any excipient. * Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms calculated from 3 electrocardiograms (ECGs) (within 15 minutes at 5 minutes apart). * Any unresolved toxicity NCI CTCAE grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Subjects with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician. Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, evidence of any acute or chronic viral illness or disease, or psychiatric illness/social situation that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent. * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], diverticulitis \[with the exception of diverticulosis\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\]). The following are exceptions to this criterion: * Subjects with vitiligo or alopecia * Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement * Any chronic skin condition that does not require systemic therapy * Subjects without active disease in the last 5 years may be included but only after consultation with the study physician * Subjects with celiac disease controlled by diet alone * History of pneumonitis or interstitial lung disease. * History of active primary immunodeficiency. * Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. * History of allogeneic organ transplantation. * Pregnant or breastfeeding. A negative serum pregnancy test is required no more than 7 days before study entry. * Subjects of reproductive potential who are not willing to employ effective birth control from screening to 1 year after the last dose of durvalumab. * History of another primary malignancy except for: * Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study treatment and low potential for risk of recurrence * Adequately treated non-melanoma skin cancer of lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * History of leptomeningeal carcinomatosis. * Patient must have no active major medical or psychosocial problems that could be complicated by study participation. * Subjects with a strong likelihood of non-adherence such as difficulties in adhering to follow-up schedule due to geographic distance from the Siteman Cancer Center should not knowingly be registered. * Individuals in whom a skinfold measurement of the cutaneous and subcutaneous tissue for eligible injection sites (left and right medial deltoid region) exceeds 40 mm. * Individuals in whom the ability to observe possible local reactions at the eligible injection sites (deltoid region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art. * Therapeutic or traumatic metal implant in the skin or muscle of either deltoid region. * Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, EKG, and/or laboratory screening test * Any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child, or chronic seizure disorder which is well controlled by medication with no seizures within the last 2 years * Syncopal episode within 12 months of screening * Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | 90 days after completion of treatment (approximately day 259) | * Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. * Assessment of the safety of neoantigen DNA vaccines will include both clinical observation and laboratory evaluation. Safety will be closely monitored after injection with eight or more clinical and laboratory assessments in the first 24 weeks of the trial |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Luminex Assay | Up to 1 year after completion of treatment (approximately 1 year and 141 days) | -Peripheral blood will be collected at multiple time points before and after vaccination |
| Number of Participants With an Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Interferon-gamma ELISPOT Assay | Up to 1 year after completion of treatment (approximately 1 year and 141 days) | The ELISpot assay was performed after in vitro culture of patient PBMC with neoantigen peptide for \ 12 days. The number of spot-forming T cells, a surrogate for the number of neoantigen-specific T cells, was determined after neoantigen peptide re-stimulation for the duration of the assay (48 hours) and compared to that of control cells that were not re-stimulated with neoantigen during the assay. One-way anova analysis was performed on replicate assessments. |
| Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD4 | Up to 1 year after completion of treatment (approximately 1 year and 141 days) | Multiparametric flow cytometry was performed as a second readout to assess neoantigen-specific T cell reactivity. Markers included CD4, CD8, IFNγ, and a viability marker. After culture, as described above, T cells were stimulated for 6 hours with/without neoantigen and stained with fluorescent antibodies specific for the various markers. Data were analyzed by comparing the percentage IFNγ+ CD4/CD8 cells between neoantigen-stimulated vs unstimulated T cells; a \>2-fold increase in percentage positive cells after neoantigen stimulation was considered positive. |
| Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD8 | Up to 1 year after completion of treatment (approximately 1 year and 141 days) | Multiparametric flow cytometry was performed as a second readout to assess neoantigen-specific T cell reactivity. Markers included CD4, CD8, IFNγ, and a viability marker. After culture, as described above, T cells were stimulated for 6 hours with/without neoantigen and stained with fluorescent antibodies specific for the various markers. Data were analyzed by comparing the percentage IFNγ+ CD4/CD8 cells between neoantigen-stimulated vs unstimulated T cells; a \>2-fold increase in percentage positive cells after neoantigen stimulation was considered positive. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Neoantigen DNA Vaccine + Durvalumab * The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1
* The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days
* For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm. | 9 |
| Neoantigen DNA Vaccine * The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1
* The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days | 9 |
| Total | 18 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 |
| Overall Study | Lack of Efficacy | 2 | 0 |
| Overall Study | Only completed 5 out of 6 vaccines | 0 | 1 |
| Overall Study | Withdrawal by Subject | 2 | 0 |
Baseline characteristics
| Characteristic | Neoantigen DNA Vaccine + Durvalumab | Total | Neoantigen DNA Vaccine |
|---|---|---|---|
| Age, Continuous | 54 years | 54.5 years | 58 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 18 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 14 Participants | 7 Participants |
| Region of Enrollment United States | 9 participants | 18 participants | 9 participants |
| Sex: Female, Male Female | 9 Participants | 18 Participants | 9 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 9 | 0 / 9 |
| other Total, other adverse events | 9 / 9 | 9 / 9 |
| serious Total, serious adverse events | 0 / 9 | 0 / 9 |
Outcome results
Primary
Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient
* Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. * Assessment of the safety of neoantigen DNA vaccines will include both clinical observation and laboratory evaluation. Safety will be closely monitored after injection with eight or more clinical and laboratory assessments in the first 24 weeks of the trial
Time frame: 90 days after completion of treatment (approximately day 259)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 anemia | 3 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 visual migraine | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 abdominal cramps | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 constipation | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 diarrhea | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 edema limbs | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 fatigue | 3 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 fever | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 urinary tract infection | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 spinal fracture | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 3-5 vascular access complication | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 alanine aminotransferase increased | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 lymphocyte count decreased | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 3-5 lymphocyte count decreased | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neutrophil count decreased | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 weight gain | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 weight loss | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 white blood cell decreased | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hyperkalemia | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hypokalemia | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 arthralgia | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 bone pain | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 dizziness | 3 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neuralgia | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 peripheral sensory neuropathy | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 breast pain | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 allergic rhinitis | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 rash maculo-papular | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 chest pain-cardiac | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 palpitations | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hypothyroidism | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 dyspepsia | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 gastritis | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 nausea | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 vomiting | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 ankle edema | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 chills | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 flu-like symptoms | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 injection site pain | 9 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 localized edema | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neck edema | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 COVID-19 infection | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 infection from cat bite | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 oral herpes lesions | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 port infection | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 upper respiratory infection | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 wound infection | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 broken foot | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 bruising | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 fall | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 anorexia | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hyperglycemia | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hyponatremia | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 myalgia | 7 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neck pain | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 pain in extremity | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 headache | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 insomnia | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 vaginal dryness | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 chest congestion | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 cough | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 dyspnea | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 rhinorrhea | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 sore throat | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 blanching of fingers on left hand | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 candidal rash | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 eczema | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 nail changes | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 nodule on breast | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 skin hyperpigmentation | 0 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 bilateral breast fat grafting | 1 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hypertension | 2 Participants |
| Neoantigen DNA Vaccine + Durvalumab | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 lymphedema | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 vomiting | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 chest pain-cardiac | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 myalgia | 7 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 visual migraine | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 ankle edema | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 abdominal cramps | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 sore throat | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 constipation | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neck pain | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 chills | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 flu-like symptoms | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 edema limbs | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 nodule on breast | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 fatigue | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 injection site pain | 9 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 fever | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 dizziness | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 urinary tract infection | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 localized edema | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 spinal fracture | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 blanching of fingers on left hand | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 3-5 vascular access complication | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neck edema | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 alanine aminotransferase increased | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neuralgia | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 lymphocyte count decreased | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 COVID-19 infection | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 3-5 lymphocyte count decreased | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 peripheral sensory neuropathy | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 neutrophil count decreased | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 infection from cat bite | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 weight gain | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 lymphedema | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 weight loss | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 oral herpes lesions | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 white blood cell decreased | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hyperglycemia | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 candidal rash | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hyperkalemia | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 port infection | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hypokalemia | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hyponatremia | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 allergic rhinitis | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 arthralgia | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 upper respiratory infection | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 bone pain | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 pain in extremity | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 skin hyperpigmentation | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 headache | 2 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 wound infection | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 eczema | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 insomnia | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 broken foot | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 breast pain | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 vaginal dryness | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 cough | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 chest congestion | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 bruising | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 rash maculo-papular | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 anemia | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hypertension | 3 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 fall | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 palpitations | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 dyspnea | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 hypothyroidism | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 diarrhea | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 anorexia | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 dyspepsia | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 nail changes | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 gastritis | 0 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 rhinorrhea | 1 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 nausea | 3 Participants |
| Neoantigen DNA Vaccine | Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Number of Adverse Events Experienced by Patient | Grade 1-2 bilateral breast fat grafting | 0 Participants |
Secondary
Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Luminex Assay
-Peripheral blood will be collected at multiple time points before and after vaccination
Time frame: Up to 1 year after completion of treatment (approximately 1 year and 141 days)
Population: The luminex assay was not able to be performed.
Secondary
Number of Participants With an Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Interferon-gamma ELISPOT Assay
The ELISpot assay was performed after in vitro culture of patient PBMC with neoantigen peptide for \ 12 days. The number of spot-forming T cells, a surrogate for the number of neoantigen-specific T cells, was determined after neoantigen peptide re-stimulation for the duration of the assay (48 hours) and compared to that of control cells that were not re-stimulated with neoantigen during the assay. One-way anova analysis was performed on replicate assessments.
Time frame: Up to 1 year after completion of treatment (approximately 1 year and 141 days)
Population: 4 participants in the Neoantigen DNA vaccine + Durvalumab arm were not evaluable due to early withdrawal from treatment (2=lack of efficacy, 2=withdrawal by subject). 2 participants in the Neoantigen DNA vaccine arm were not evaluable due to early withdrawal from treatment (1=adverse event, 1=only 5 out of 6 vaccines received).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Neoantigen DNA Vaccine + Durvalumab | Number of Participants With an Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Interferon-gamma ELISPOT Assay | 3 Participants |
| Neoantigen DNA Vaccine | Number of Participants With an Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Interferon-gamma ELISPOT Assay | 6 Participants |
Secondary
Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD4
Multiparametric flow cytometry was performed as a second readout to assess neoantigen-specific T cell reactivity. Markers included CD4, CD8, IFNγ, and a viability marker. After culture, as described above, T cells were stimulated for 6 hours with/without neoantigen and stained with fluorescent antibodies specific for the various markers. Data were analyzed by comparing the percentage IFNγ+ CD4/CD8 cells between neoantigen-stimulated vs unstimulated T cells; a \>2-fold increase in percentage positive cells after neoantigen stimulation was considered positive.
Time frame: Up to 1 year after completion of treatment (approximately 1 year and 141 days)
Population: 4 participants in the Neoantigen DNA vaccine + Durvalumab arm were not evaluable due to early withdrawal from treatment (2=lack of efficacy, 2=withdrawal by subject). 2 participants in the Neoantigen DNA vaccine arm were not evaluable due to early withdrawal from treatment (1=adverse event, 1=only 5 out of 6 vaccines received).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Neoantigen DNA Vaccine + Durvalumab | Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD4 | 3 Participants |
| Neoantigen DNA Vaccine | Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD4 | 4 Participants |
Secondary
Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD8
Multiparametric flow cytometry was performed as a second readout to assess neoantigen-specific T cell reactivity. Markers included CD4, CD8, IFNγ, and a viability marker. After culture, as described above, T cells were stimulated for 6 hours with/without neoantigen and stained with fluorescent antibodies specific for the various markers. Data were analyzed by comparing the percentage IFNγ+ CD4/CD8 cells between neoantigen-stimulated vs unstimulated T cells; a \>2-fold increase in percentage positive cells after neoantigen stimulation was considered positive.
Time frame: Up to 1 year after completion of treatment (approximately 1 year and 141 days)
Population: 4 participants in the Neoantigen DNA vaccine + Durvalumab arm were not evaluable due to early withdrawal from treatment (2=lack of efficacy, 2=withdrawal by subject). 2 participants in the Neoantigen DNA vaccine arm were not evaluable due to early withdrawal from treatment (1=adverse event, 1=only 5 out of 6 vaccines received).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Neoantigen DNA Vaccine + Durvalumab | Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD8 | 3 Participants |
| Neoantigen DNA Vaccine | Number of Participants With Immune Response to Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab as Measured by Multiparametric Flow Cytometry - CD8 | 5 Participants |